• Carcinoid Syndrome Diarrhea Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors / Traders including Marketing Channel, Market Positioning and Distributors / Traders List.
• Market Effect Factors Analysis including Technology Progress / Risk, Consumer Needs / Customer Preference Change and Economic / Political Environmental Change.
• Carcinoid Syndrome Diarrhea Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Global Carcinoid Syndrome Diarrhea Treatment Market Taxonomy: By Treatment Type:
• Chemotherapy
• Oral Therapy
• Somatostatin Analog( SSA) Therapy
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Novel ground-breaking therapy to provide immense opportunities for market growth
In February 2017, Lexicon Pharmaceutical Inc., announced that the U. S. Food and Drug Administration( FDA) approved Xermelo( Telotristat etiprate) as the first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy( SSA) for adults. Xermelo mainly targets the overproduction of serotonin hormone inside mNET cells and reduces the frequency of carcinoid syndrome diarrhea. Furthermore, in 2017, Ipsen Biopharmaceutical, announced the U. S. Food and Drug Administration( FDA) approval for a supplemental indication of Somatuline Depot( lanreotide) Injection 120 mg for the treatment of carcinoid syndrome, to reduce the frequency of shortacting somatostatin analogue rescue therapy.